

2019 Future of Opioid/Opium Addiction R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

<https://marketpublishers.com/r/239F6943CECEN.html>

Date: February 2019

Pages: 90

Price: US\$ 2,199.00 (Single User License)

ID: 239F6943CECEN

Abstracts

The global demand for Opioid/Opium Addiction treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Opioid/Opium Addiction pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Opioid/Opium Addiction pipeline companies from advancing their products into Phase 3 or Phase 4.

Opioid/Opium Addiction Report Description-

The 2019 pipeline study on Opioid/Opium Addiction pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Opioid/Opium Addiction pipeline compounds.

The Opioid/Opium Addiction pipeline guide presents information on all active drugs currently being developed for Opioid/Opium Addiction. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Opioid/Opium Addiction pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Opioid/Opium Addiction drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Opioid/Opium Addiction product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Opioid/Opium Addiction pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Opioid/Opium Addiction pipeline report includes-

An overview of Opioid/Opium Addiction disease including symptoms, causes, diagnosis and available treatment options is provided.

Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc

Phase wise count of Opioid/Opium Addiction pipeline

Company wise list of Opioid/Opium Addiction pipeline

Mechanism of Action wise Opioid/Opium Addiction pipeline

For each pipeline candidate, the following details are provided

Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)

Current status of development

Drug overview

Mechanism of Action

Pre-clinical and Clinical Trials/Results

Company Overview and Recent Developments

REASONS TO BUY

The report is designed to help industry executives promote the success and continued growth of their organizations

Get clear understanding of the entire Opioid/Opium Addiction pipeline, with details on active projects

Stay ahead of the competition through comprehensive knowledge of Opioid/Opium Addiction pipeline progress

Get in detail information of each product with updated information on each project along with key milestones

Gain clear insights into companies participating in Opioid/Opium Addiction pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

Contents

1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2. GLOBAL OPIOID/OPIUM ADDICTION PIPELINE OVERVIEW

- 2.1 Key Findings, 2019
- 2.2 Disease Overview
- 2.3 Research Methodology

3. EXECUTIVE SUMMARY

- 3.1 Opioid/Opium Addiction Drugs under active development, H1- 2019
- 3.2 Pipeline Drugs in Early Stage of Development
 - 3.2.1 Pre-clinical
 - 3.2.2 Discovery
 - 3.2.3 Phase
 - 3.2.4Phase
- 3.3 Pipeline Drugs in Advanced Stage of Development
 - 3.3.1 Phase
 - 3.3.2 Pre-registration
- 3.4 Companies involved in Opioid/Opium Addiction pipeline, H1- 2019
- 3.5 Mechanism of Action wise Opioid/Opium Addiction Pipeline Candidates

4 ADAPT PHARMA LTD OPIOID/OPIUM ADDICTION PIPELINE DETAILS

- 4.1 Adapt Pharma Ltd Business Profile
- 4.2 Adapt Pharma Ltd Opioid/Opium Addiction Drug Details
- 4.3 Drug Snapshot
 - 4.3.1 Originator
 - 4.3.2 Collaborator/Co-Developer
 - 4.3.3 Route of Administration
 - 4.3.4 Orphan Drug/Fast Track/Special Designation
 - 4.3.5 Geography
 - 4.3.6 Type of Molecular Entity
 - 4.3.7 Current Status

- 4.4 Drug Overview
- 4.5 Drug Mechanism of Action
- 4.6 Clinical/Pre-clinical Trial Details
- 4.7 Latest Drug Developments

5 ADDEX THERAPEUTICS LTD OPIOID/OPIUM ADDICTION PIPELINE DETAILS

- 5.1 Addex Therapeutics Ltd Business Profile
- 5.2 Addex Therapeutics Ltd Opioid/Opium Addiction Drug Details
- 5.3 Drug Snapshot
 - 5.3.1 Originator
 - 5.3.2 Collaborator/Co-Developer
 - 5.3.3 Route of Administration
 - 5.3.4 Orphan Drug/Fast Track/Special Designation
 - 5.3.5 Geography
 - 5.3.6 Type of Molecular Entity
 - 5.3.7 Current Status
- 5.4 Drug Overview
- 5.5 Drug Mechanism of Action
- 5.6 Clinical/Pre-clinical Trial Details
- 5.7 Latest Drug Developments

6 AMYGDALA NEUROSCIENCES INC OPIOID/OPIUM ADDICTION PIPELINE DETAILS

- 6.1 Amygdala Neurosciences Inc Business Profile
- 6.2 Amygdala Neurosciences Inc Opioid/Opium Addiction Drug Details
- 6.3 Drug Snapshot
 - 6.3.1 Originator
 - 6.3.2 Collaborator/Co-Developer
 - 6.3.3 Route of Administration
 - 6.3.4 Orphan Drug/Fast Track/Special Designation
 - 6.3.5 Geography
 - 6.3.6 Type of Molecular Entity
 - 6.3.7 Current Status
- 6.4 Drug Overview
- 6.5 Drug Mechanism of Action
- 6.6 Clinical/Pre-clinical Trial Details
- 6.7 Latest Drug Developments

7 AXIM BIOTECHNOLOGIES INC OPIOID/OPIUM ADDICTION PIPELINE DETAILS

- 7.1 Axim Biotechnologies Inc Business Profile
- 7.2 Axim Biotechnologies Inc Opioid/Opium Addiction Drug Details
- 7.3 Drug Snapshot
 - 7.3.1 Originator
 - 7.3.2 Collaborator/Co-Developer
 - 7.3.3 Route of Administration
 - 7.3.4 Orphan Drug/Fast Track/Special Designation
 - 7.3.5 Geography
 - 7.3.6 Type of Molecular Entity
 - 7.3.7 Current Status
- 7.4 Drug Overview
- 7.5 Drug Mechanism of Action
- 7.6 Clinical/Pre-clinical Trial Details
- 7.7 Latest Drug Developments

8 BIOCORRX INC OPIOID/OPIUM ADDICTION PIPELINE DETAILS

- 8.1 BioCorRx Inc Business Profile
- 8.2 BioCorRx Inc Opioid/Opium Addiction Drug Details
- 8.3 Drug Snapshot
 - 8.3.1 Originator
 - 8.3.2 Collaborator/Co-Developer
 - 8.3.3 Route of Administration
 - 8.3.4 Orphan Drug/Fast Track/Special Designation
 - 8.3.5 Geography
 - 8.3.6 Type of Molecular Entity
 - 8.3.7 Current Status
- 8.4 Drug Overview
- 8.5 Drug Mechanism of Action
- 8.6 Clinical/Pre-clinical Trial Details
- 8.7 Latest Drug Developments

9 BIODELIVERY SCIENCES INTERNATIONAL INC OPIOID/OPIUM ADDICTION PIPELINE DETAILS

- 9.1 BioDelivery Sciences International Inc Business Profile

9.2 BioDelivery Sciences International Inc Opioid/Opium Addiction Drug Details

9.3 Drug Snapshot

9.3.1 Originator

9.3.2 Collaborator/Co-Developer

9.3.3 Route of Administration

9.3.4 Orphan Drug/Fast Track/Special Designation

9.3.5 Geography

9.3.6 Type of Molecular Entity

9.3.7 Current Status

9.4 Drug Overview

9.5 Drug Mechanism of Action

9.6 Clinical/Pre-clinical Trial Details

9.7 Latest Drug Developments

10 CAMURUS AB OPIOID/OPIUM ADDICTION PIPELINE DETAILS

10.1 Camurus AB Business Profile

10.2 Camurus AB Opioid/Opium Addiction Drug Details

10.3 Drug Snapshot

10.3.1 Originator

10.3.2 Collaborator/Co-Developer

10.3.3 Route of Administration

10.3.4 Orphan Drug/Fast Track/Special Designation

10.3.5 Geography

10.3.6 Type of Molecular Entity

10.3.7 Current Status

10.4 Drug Overview

10.5 Drug Mechanism of Action

10.6 Clinical/Pre-clinical Trial Details

10.7 Latest Drug Developments

11 FORESEE PHARMACEUTICALS CO LTD OPIOID/OPIUM ADDICTION PIPELINE DETAILS

11.1 Foresee Pharmaceuticals Co Ltd Business Profile

11.2 Foresee Pharmaceuticals Co Ltd Opioid/Opium Addiction Drug Details

11.3 Drug Snapshot

11.3.1 Originator

11.3.2 Collaborator/Co-Developer

- 11.3.3 Route of Administration
- 11.3.4 Orphan Drug/Fast Track/Special Designation
- 11.3.5 Geography
- 11.3.6 Type of Molecular Entity
- 11.3.7 Current Status
- 11.4 Drug Overview
- 11.5 Drug Mechanism of Action
- 11.6 Clinical/Pre-clinical Trial Details
- 11.7 Latest Drug Developments

12 INDIVIOR PLC OPIOID/OPIUM ADDICTION PIPELINE DETAILS

- 12.1 Indivior Plc Business Profile
- 12.2 Indivior Plc Opioid/Opium Addiction Drug Details
- 12.3 Drug Snapshot
 - 12.3.1 Originator
 - 12.3.2 Collaborator/Co-Developer
 - 12.3.3 Route of Administration
 - 12.3.4 Orphan Drug/Fast Track/Special Designation
 - 12.3.5 Geography
 - 12.3.6 Type of Molecular Entity
 - 12.3.7 Current Status
- 12.4 Drug Overview
- 12.5 Drug Mechanism of Action
- 12.6 Clinical/Pre-clinical Trial Details
- 12.7 Latest Drug Developments

13 INSYS THERAPEUTICS INC OPIOID/OPIUM ADDICTION PIPELINE DETAILS

- 13.1 Insys Therapeutics Inc Business Profile
- 13.2 Insys Therapeutics Inc Opioid/Opium Addiction Drug Details
- 13.3 Drug Snapshot
 - 13.3.1 Originator
 - 13.3.2 Collaborator/Co-Developer
 - 13.3.3 Route of Administration
 - 13.3.4 Orphan Drug/Fast Track/Special Designation
 - 13.3.5 Geography
 - 13.3.6 Type of Molecular Entity
 - 13.3.7 Current Status

- 13.4 Drug Overview
- 13.5 Drug Mechanism of Action
- 13.6 Clinical/Pre-clinical Trial Details
- 13.7 Latest Drug Developments

14 KANDY THERAPEUTICS LTD OPIOID/OPIUM ADDICTION PIPELINE DETAILS

- 14.1 Kandy Therapeutics Ltd Business Profile
- 14.2 Kandy Therapeutics Ltd Opioid/Opium Addiction Drug Details
- 14.3 Drug Snapshot
 - 14.3.1 Originator
 - 14.3.2 Collaborator/Co-Developer
 - 14.3.3 Route of Administration
 - 14.3.4 Orphan Drug/Fast Track/Special Designation
 - 14.3.5 Geography
 - 14.3.6 Type of Molecular Entity
 - 14.3.7 Current Status
- 14.4 Drug Overview
- 14.5 Drug Mechanism of Action
- 14.6 Clinical/Pre-clinical Trial Details
- 14.7 Latest Drug Developments

15 NOVARTIS AG OPIOID/OPIUM ADDICTION PIPELINE DETAILS

- 15.1 Novartis AG Business Profile
- 15.2 Novartis AG Opioid/Opium Addiction Drug Details
- 15.3 Drug Snapshot
 - 15.3.1 Originator
 - 15.3.2 Collaborator/Co-Developer
 - 15.3.3 Route of Administration
 - 15.3.4 Orphan Drug/Fast Track/Special Designation
 - 15.3.5 Geography
 - 15.3.6 Type of Molecular Entity
 - 15.3.7 Current Status
- 15.4 Drug Overview
- 15.5 Drug Mechanism of Action
- 15.6 Clinical/Pre-clinical Trial Details
- 15.7 Latest Drug Developments

16 OMEROS CORP OPIOID/OPIUM ADDICTION PIPELINE DETAILS

- 16.1 Omeros Corp Business Profile
- 16.2 Omeros Corp Opioid/Opium Addiction Drug Details
- 16.3 Drug Snapshot
 - 16.3.1 Originator
 - 16.3.2 Collaborator/Co-Developer
 - 16.3.3 Route of Administration
 - 16.3.4 Orphan Drug/Fast Track/Special Designation
 - 16.3.5 Geography
 - 16.3.6 Type of Molecular Entity
 - 16.3.7 Current Status
- 16.4 Drug Overview
- 16.5 Drug Mechanism of Action
- 16.6 Clinical/Pre-clinical Trial Details
- 16.7 Latest Drug Developments

17 OPIANT PHARMACEUTICALS INC OPIOID/OPIUM ADDICTION PIPELINE DETAILS

- 17.1 Opiant Pharmaceuticals Inc Business Profile
- 17.2 Opiant Pharmaceuticals Inc Opioid/Opium Addiction Drug Details
- 17.3 Drug Snapshot
 - 17.3.1 Originator
 - 17.3.2 Collaborator/Co-Developer
 - 17.3.3 Route of Administration
 - 17.3.4 Orphan Drug/Fast Track/Special Designation
 - 17.3.5 Geography
 - 17.3.6 Type of Molecular Entity
 - 17.3.7 Current Status
- 17.4 Drug Overview
- 17.5 Drug Mechanism of Action
- 17.6 Clinical/Pre-clinical Trial Details
- 17.7 Latest Drug Developments

18 OREXIGEN THERAPEUTICS INC OPIOID/OPIUM ADDICTION PIPELINE DETAILS

- 18.1 Orexigen Therapeutics Inc Business Profile

18.2 Orexigen Therapeutics Inc Opioid/Opium Addiction Drug Details

18.3 Drug Snapshot

18.3.1 Originator

18.3.2 Collaborator/Co-Developer

18.3.3 Route of Administration

18.3.4 Orphan Drug/Fast Track/Special Designation

18.3.5 Geography

18.3.6 Type of Molecular Entity

18.3.7 Current Status

18.4 Drug Overview

18.5 Drug Mechanism of Action

18.6 Clinical/Pre-clinical Trial Details

18.7 Latest Drug Developments

19 OREXO OPIOID/OPIUM ADDICTION PIPELINE DETAILS

19.1 Orexo Business Profile

19.2 Orexo Opioid/Opium Addiction Drug Details

19.3 Drug Snapshot

19.3.1 Originator

19.3.2 Collaborator/Co-Developer

19.3.3 Route of Administration

19.3.4 Orphan Drug/Fast Track/Special Designation

19.3.5 Geography

19.3.6 Type of Molecular Entity

19.3.7 Current Status

19.4 Drug Overview

19.5 Drug Mechanism of Action

19.6 Clinical/Pre-clinical Trial Details

19.7 Latest Drug Developments

20 PFIZER INC OPIOID/OPIUM ADDICTION PIPELINE DETAILS

20.1 Pfizer Inc Business Profile

20.2 Pfizer Inc Opioid/Opium Addiction Drug Details

20.3 Drug Snapshot

20.3.1 Originator

20.3.2 Collaborator/Co-Developer

20.3.3 Route of Administration

- 20.3.4 Orphan Drug/Fast Track/Special Designation
- 20.3.5 Geography
- 20.3.6 Type of Molecular Entity
- 20.3.7 Current Status
- 20.4 Drug Overview
- 20.5 Drug Mechanism of Action
- 20.6 Clinical/Pre-clinical Trial Details
- 20.7 Latest Drug Developments

21 PHARMAZZ INC OPIOID/OPIUM ADDICTION PIPELINE DETAILS

- 21.1 Pharmazz Inc Business Profile
- 21.2 Pharmazz Inc Opioid/Opium Addiction Drug Details
- 21.3 Drug Snapshot
 - 21.3.1 Originator
 - 21.3.2 Collaborator/Co-Developer
 - 21.3.3 Route of Administration
 - 21.3.4 Orphan Drug/Fast Track/Special Designation
 - 21.3.5 Geography
 - 21.3.6 Type of Molecular Entity
 - 21.3.7 Current Status
- 21.4 Drug Overview
- 21.5 Drug Mechanism of Action
- 21.6 Clinical/Pre-clinical Trial Details
- 21.7 Latest Drug Developments

22 RELMADA THERAPEUTICS INC OPIOID/OPIUM ADDICTION PIPELINE DETAILS

- 22.1 Relmada Therapeutics Inc Business Profile
- 22.2 Relmada Therapeutics Inc Opioid/Opium Addiction Drug Details
- 22.3 Drug Snapshot
 - 22.3.1 Originator
 - 22.3.2 Collaborator/Co-Developer
 - 22.3.3 Route of Administration
 - 22.3.4 Orphan Drug/Fast Track/Special Designation
 - 22.3.5 Geography
 - 22.3.6 Type of Molecular Entity
 - 22.3.7 Current Status

- 22.4 Drug Overview
- 22.5 Drug Mechanism of Action
- 22.6 Clinical/Pre-clinical Trial Details
- 22.7 Latest Drug Developments

23 SAVANT HWP INC OPIOID/OPIUM ADDICTION PIPELINE DETAILS

- 23.1 Savant HWP Inc Business Profile
- 23.2 Savant HWP Inc Opioid/Opium Addiction Drug Details
- 23.3 Drug Snapshot
 - 23.3.1 Originator
 - 23.3.2 Collaborator/Co-Developer
 - 23.3.3 Route of Administration
 - 23.3.4 Orphan Drug/Fast Track/Special Designation
 - 23.3.5 Geography
 - 23.3.6 Type of Molecular Entity
 - 23.3.7 Current Status
- 23.4 Drug Overview
- 23.5 Drug Mechanism of Action
- 23.6 Clinical/Pre-clinical Trial Details
- 23.7 Latest Drug Developments

24 SERINA THERAPEUTICS INC OPIOID/OPIUM ADDICTION PIPELINE DETAILS

- 24.1 Serina Therapeutics Inc Business Profile
- 24.2 Serina Therapeutics Inc Opioid/Opium Addiction Drug Details
- 24.3 Drug Snapshot
 - 24.3.1 Originator
 - 24.3.2 Collaborator/Co-Developer
 - 24.3.3 Route of Administration
 - 24.3.4 Orphan Drug/Fast Track/Special Designation
 - 24.3.5 Geography
 - 24.3.6 Type of Molecular Entity
 - 24.3.7 Current Status
- 24.4 Drug Overview
- 24.5 Drug Mechanism of Action
- 24.6 Clinical/Pre-clinical Trial Details
- 24.7 Latest Drug Developments

25 TITAN PHARMACEUTICALS INC OPIOID/OPIUM ADDICTION PIPELINE DETAILS

- 25.1 Titan Pharmaceuticals Inc Business Profile
- 25.2 Titan Pharmaceuticals Inc Opioid/Opium Addiction Drug Details
- 25.3 Drug Snapshot
 - 25.3.1 Originator
 - 25.3.2 Collaborator/Co-Developer
 - 25.3.3 Route of Administration
 - 25.3.4 Orphan Drug/Fast Track/Special Designation
 - 25.3.5 Geography
 - 25.3.6 Type of Molecular Entity
 - 25.3.7 Current Status
- 25.4 Drug Overview
- 25.5 Drug Mechanism of Action
- 25.6 Clinical/Pre-clinical Trial Details
- 25.7 Latest Drug Developments

26 XALUD THERAPEUTICS INC OPIOID/OPIUM ADDICTION PIPELINE DETAILS

- 26.1 Xalud Therapeutics Inc Business Profile
- 26.2 Xalud Therapeutics Inc Opioid/Opium Addiction Drug Details
- 26.3 Drug Snapshot
 - 26.3.1 Originator
 - 26.3.2 Collaborator/Co-Developer
 - 26.3.3 Route of Administration
 - 26.3.4 Orphan Drug/Fast Track/Special Designation
 - 26.3.5 Geography
 - 26.3.6 Type of Molecular Entity
 - 26.3.7 Current Status
- 26.4 Drug Overview
- 26.5 Drug Mechanism of Action
- 26.6 Clinical/Pre-clinical Trial Details
- 26.7 Latest Drug Developments

27 ZYNERBA PHARMACEUTICALS INC OPIOID/OPIUM ADDICTION PIPELINE DETAILS

- 27.1 Zynerba Pharmaceuticals Inc Business Profile

27.2 Zynerba Pharmaceuticals Inc Opioid/Opium Addiction Drug Details

27.3 Drug Snapshot

27.3.1 Originator

27.3.2 Collaborator/Co-Developer

27.3.3 Route of Administration

27.3.4 Orphan Drug/Fast Track/Special Designation

27.3.5 Geography

27.3.6 Type of Molecular Entity

27.3.7 Current Status

27.4 Drug Overview

27.5 Drug Mechanism of Action

27.6 Clinical/Pre-clinical Trial Details

27.7 Latest Drug Developments

28. LATEST OPIOID/OPIUM ADDICTION DRUG PIPELINE DEVELOPMENTS, 2019

29. APPENDIX

29.1 About Us

29.2 Sources and Methodology

29.3 Contact Information

I would like to order

Product name: 2019 Future of Opioid/Opium Addiction R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

Product link: <https://marketpublishers.com/r/239F6943CECEN.html>

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/239F6943CECEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

